|By Marketwired .||
|October 29, 2013 06:59 PM EDT||
AURORA, ON -- (Marketwired) -- 10/29/13 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced financial results for the year ended July 31, 2013.
The following are selected highlights during the 2013 fiscal year and subsequent to year-end:
- Announced receipt, on October 28, 2013, of subscription agreements for net proceeds in excess of $4,600,000. The terms of the private placement are for the purchase of common shares at $1.15 per share and include one warrant per share at an exercise price of $1.61 and have an expiry of five years from the date of issue. The completion of the private placement is subject to approval by the Toronto Stock Exchange;
- Completed first patient enrollment and dose administration in addition to recently completing an interim review of data collected for the first four cohorts in the Company's ongoing European Phase I/II clinical study of L-DOS47 in Poland. On October 15, 2013, the Company announced the completion of an interim review of data collected to date in this study. The data to date have shown that L-DOS47 was well-tolerated for all patients within all cohorts. Duration of treatment has increased with each dose escalation, including one patient that was dosed for approximately 18 weeks without disease progression. We remain on plan for the completion of the Phase I component of the trial by the summer of 2014 and a formal analysis of the data will be conducted following collection of all data at the completion of the study.
- Completed the sale of its Rivex Pharma division on January 25, 2013;
- Implemented changes to the board of directors resulted in the appointments of Sławomir Ludwikowski, Professor Sławomir Majewski and Mr. Stacy L. Wills;
- Announced its intention to change the Company's auditors from KPMG LLP to BDO Canada LLP, effective following the completion of the Company's fiscal 2013 audit by KPMG LLP, with a transition period that commenced on June 21, 2013;
- Established Helix Polska sp.z o.o., further strengthening Canadian-Polish relationships and scientific collaboration which began in 2005, when Polish investors first became shareholders of the Company;
- Terminated the material transfer and license agreement with Merck & Co. Inc. for the Company's Topical Interferon Alpha-2b drug development program and in addition closed the Saskatoon laboratory. The Company has now limited ongoing activities relating to its Tropical Interferon Alpha-2b to sourcing and qualifying alternative interferon alpha-2b raw material samples, and finding suitable strategic partner(s) who would be willing to license or acquire the product and support the remaining development costs through to commercial launch.
The Company recorded a net loss and total comprehensive loss of $1,545,000 ($0.02 loss per common share) and $17,423,000 ($0.26 loss per common share) for the fiscal years ended 2013 and 2012, respectively.
The net loss and comprehensive loss of $1,545,000 for the fiscal year ended 2013 includes a gain on sale from discontinued operations totaling $6,019,000 (2012 - $nil) and net income from discontinued operations totaling $630,000 (2012 - $1,431,000). On January 25, 2013, the Company announced the sale of its distribution business in Canada. In fiscal 2012 the Company realized a one-time charge of $6,536,000 (2013 - $nil) related to Special Committee and Settlement expenditures in connection with the 2012 AGM.
Excluding the gain on sale and the net income and total comprehensive income from discontinued operations, the Company realized a net loss and total comprehensive loss from continuing operations of $8,194,000 ($0.12 loss per common share) and $18,854,000 ($0.28 loss per common share) for the fiscal years ended 2013 and 2012, respectively.
Research and development
Research and development costs for fiscal 2013 and 2012 totalled $5,032,000 and $7,450,000, respectively, with the bulk of the research and development costs represented by L-DOS47, Topical Interferon Alpha-2b and Corporate research and development initiatives.
L-DOS47 research and development expenses for fiscal 2013 and 2012 totalled $2,771,000 and $3,581,000, respectively. L-DOS47 research and development expenditures mainly reflect expenditures associated with the ongoing European Phase I/II clinical study in Poland.
Topical Interferon Alpha-2b research and development expenses for fiscal 2013 and 2012 totalled $774,000 and $1,631,000, respectively. Beginning in June 2012, the Company initiated a downsizing of the staff in the Saskatoon laboratory which ultimately resulted in the close of the facility in November 2012. The Company has now limited ongoing activities relating to its Tropical Interferon Alpha-2b to sourcing and qualifying alternative interferon alpha-2b raw material samples, strengthening the BiPhasix patent portfolio and finding suitable strategic partner(s) who would be willing to license or acquire the product and support the remaining development costs through to commercial launch.
The Company also incurs corporate research and development expenses. Corporate research and development expenses totalled $1,081,000 and $1,407,000 respectively for the fiscal periods ended July 31, 2013 and 2012. The lower expenses can be attributed to a reduction in payroll expense associated with headcount reductions of corporate research and development employees in fiscal 2012 in addition to a reduction in travel, consulting and insurance related expenses.
Operating, general and administration
Operating, general and administration expenses for the fiscal years ended 2013 and 2012 totalled $3,196,000 and $4,580,000, respectively and represents a decrease of $1,384,000 (30.2%) when compared to fiscal 2012. Lower operating, general and administration expenses are the result of cost cutting measures by the Company, which include reductions related to lower legal and audit fees as a result of the Company having voluntarily surrendered its listing on the NYSE-MKT exchange in the United States, lower stock-based compensation expenses, reduced headcount and investor relations outsourcing activities.
Special committee and settlement agreement
All expenses relating to the Company's contested annual general meeting of shareholders in January 2012 and the related activities of the special committee and settlement agreement were incurred during fiscal 2012.
LIQUIDITY AND CAPITAL RESOURCES
The Company's cash reserves of $4,493,000 as at July 31, 2013 are insufficient to meet anticipated cash needs for working capital and capital expenditures through the next twelve months, nor are they sufficient to see the current research and development initiates through to completion. To the extent that the Company does not believe it has sufficient liquidity to meet its current obligations, management considers securing additional funds, primarily through the issuance of equity securities of the Company, to be of the utmost importance.
The Company's consolidated fiscal 2013 and 2012 financial statements are summarized below.
Consolidated Statements of Net Loss and Comprehensive Loss (thousand $, except for per share data) 2013 2012 --------- --------- Expenses: Research and development 5,032 7,450 Operating, general & administration 3,196 4,580 Special committee & settlement agreement - 6,536 Loss (gain) on disposal and impairment on property, plant and equipment (18) 320 --------- --------- Results from operating activities before finance items (8,210) (18,886) Finance items 16 32 --------- --------- Loss and total comprehensive lossfrom continuing operations (8,194) (18,854) Net income and total comprehensive income from discontinued operations 630 1,431 Gain fro msale of discontinued operations 6,019 - --------- --------- Net loss and total comprehensive loss (1,545) (17,423) ========= ========= Loss per share from continuing operations * $ (0.12) $ (0.28) Income per share from discontinued operations * $ 0.01 $ 0.02 Gain per share from sale of discontinued operations * $ 0.09 $ - Total loss per common share * $ (0.02) $ (0.26) * Figures are for both basic and fully diluted
Consolidated Statements of Cash Flows (thousand $) 2013 2012 --------- --------- Cash provided by (used in): Net loss and total comprehensive loss (8,194) (18,854) Items not involving cash: Depreciation of property, plant and equipment 396 699 Deferred lease credit (25) (25) Stock-based compensation 241 1,347 Stock-based consideration - 69 Foreign exchange loss 9 76 Loss on disposal and impairment on property, plant and equipment (18) 320 --------- --------- (7,591) (16,368) Changes in non-cash working capital (223) 828 --------- --------- Operating activities (7,814) (15,540) Financing activities - 43 Investing activities (6) (37) Effect of exchange rate changes on cash (9) (76) --------- --------- Net decrease in cash from continuing operations (7,829) (15,610) Net increase in cash from discontinued operations 7,460 1,428 Cash beginning of the year 4,862 19,044 --------- --------- Cash end of the year 4,493 4,862 ========= ========= Consolidated Statement of Financial Position (thousand $) 2013 2012 ---------- ---------- Non current assets 677 1,493 Current assets: Prepaids 139 107 Inventory - 421 Accounts receivable 559 733 Cash 4,493 4,862 ---------- ---------- 5,191 6,123 ---------- ---------- Total assets 5,868 7,616 ========== ========== Shareholders' equity 4,920 6,224 Non current liabilities - 23 Current liabilities: Deferred lease credit 23 25 Accrued liabilities 621 694 Accounts payable 304 650 ---------- ---------- 948 1,369 ---------- ---------- Total liabilities & shareholders equity 5,868 7,616 ========== ==========
The Company's complete 2013 Consolidated Financial Statements, Management's Discussion and Analysis and Annual Information Form are being filed today with Canadian securities regulatory authorities and will be available at www.sedar.com, as well as on the Company's website at www.helixbiopharma.com. Shareholders have the ability to receive a hard copy of the Company's complete audited financial statements free of charge upon request.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".
Forward-Looking Statements and Risks and Uncertainties
This news release contains forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates; statements regarding plans, goals, objectives, intentions and expectations with respect to the Company's future business, operations, research and development, including the focus of the Company on its two drug candidates, L-DOS47 and Topical Interferon Alpha-2b (cervical lesions indication) and other information in future periods.
Forward-looking statements include, without limitation, statements concerning (i) the Company's ability to operate on a going concern being dependent mainly on obtaining additional financing; (ii) the Company's growth and future prospects being dependent on the success of one or both of L-DOS47 and Topical Interferon Alpha-2b; (iii) the Company's priority continuing to be L-DOS47; (iv) the Company's development programs for Topical Interferon Alpha-2b, DOS47 and L-DOS47, including but not limited to, extension of the drug candidates to other indications and the identification and development of further tumour-targeting antibodies for DOS47; (v) the Company's Polish Phase I/II clinical trials for L-DOS47; (vi) future expenditures, insufficiency of the Company's current cash resources and the need for financing and cost-cutting and/or cost-deferral measures; (vii) future financing requirements, the seeking of additional funding and anticipated future operating losses; and (viii) the acceptance of the private placement by the Toronto Stock Exchange, the closing of the private placement and the expected amount of the gross proceeds and the net proceeds to be received in connection with the private placement. Forward-looking statements can further be identified by the use of forward-looking terminology such as "2013", "2014", ongoing" or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions "will", "may", "could", "would", or "should" occur or be achieved, or comparable terminology referring to future events or results.
Forward-looking statements are statements about the future and are inherently uncertain, and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management's current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release, including, but not limited to, the safety and efficacy of L-DOS47 and Topical Interferon Alpha-2b (low-grade cervical lesions); that sufficient financing will be obtained in a timely manner to allow the Company to continue operations; the timely provision of services and supplies, including Interferon alpha-2b raw materials, or other performance of contracts by third parties; future costs; the absence of any material changes in business strategy or plans; the timely receipt of required regulatory approvals and strategic partner support; and the acceptance of the private placement by the Toronto Stock Exchange, the closing of the private placement and the expected amount of the net proceeds to be received in connection with the private placement.
The Company's actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including without limitation, the risk that the Company's assumptions may prove to be incorrect; the risk that additional financing may not be obtainable in a timely manner, or at all (including that the Toronto Stock Exchange may not accept the private placement and/or that the private placement may not close or that the actual amount of the net proceeds may be lower than anticipated), and that clinical trials may not commence or complete within anticipated timelines or may fail; third party suppliers of necessary services or of drug product and other materials may fail to perform or be unwilling or unable to supply the Company, which could cause delay or cancellation of the Company's research and development or distribution activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to secure necessary strategic partner support; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; and other risks and uncertainties referred to elsewhere in this news release, any of which could cause actual results to vary materially from current results or the Company's anticipated future results. Certain of these risks and uncertainties, and others affecting the Company, are more fully described in Helix's Annual Report, in particular under the headings "Forward-looking Statements" and "Risk Factors", and other reports filed under Helix's profile on SEDAR at www.sedar.com from time to time at. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management on the date of this new release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.
Helix BioPharma Corp.
Tel: 905 841-2300
Email: [email protected]
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
Dec. 8, 2016 12:30 AM EST Reads: 1,097
The Internet of Things (IoT) promises to simplify and streamline our lives by automating routine tasks that distract us from our goals. This promise is based on the ubiquitous deployment of smart, connected devices that link everything from industrial control systems to automobiles to refrigerators. Unfortunately, comparatively few of the devices currently deployed have been developed with an eye toward security, and as the DDoS attacks of late October 2016 have demonstrated, this oversight can ...
Dec. 8, 2016 12:15 AM EST Reads: 1,321
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 7, 2016 11:45 PM EST Reads: 987
What happens when the different parts of a vehicle become smarter than the vehicle itself? As we move toward the era of smart everything, hundreds of entities in a vehicle that communicate with each other, the vehicle and external systems create a need for identity orchestration so that all entities work as a conglomerate. Much like an orchestra without a conductor, without the ability to secure, control, and connect the link between a vehicle’s head unit, devices, and systems and to manage the ...
Dec. 7, 2016 10:30 PM EST Reads: 844
"Once customers get a year into their IoT deployments, they start to realize that they may have been shortsighted in the ways they built out their deployment and the key thing I see a lot of people looking at is - how can I take equipment data, pull it back in an IoT solution and show it in a dashboard," stated Dave McCarthy, Director of Products at Bsquare Corporation, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 7, 2016 10:00 PM EST Reads: 1,189
In his session at Cloud Expo, Robert Cohen, an economist and senior fellow at the Economic Strategy Institute, provideed economic scenarios that describe how the rapid adoption of software-defined everything including cloud services, SDDC and open networking will change GDP, industry growth, productivity and jobs. This session also included a drill down for several industries such as finance, social media, cloud service providers and pharmaceuticals.
Dec. 7, 2016 09:15 PM EST Reads: 361
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
Dec. 7, 2016 08:45 PM EST Reads: 1,632
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, discussed the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Dec. 7, 2016 08:15 PM EST Reads: 2,210
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of Soli...
Dec. 7, 2016 07:15 PM EST Reads: 1,802
Enterprise IT has been in the era of Hybrid Cloud for some time now. But it seems most conversations about Hybrid are focused on integrating AWS, Microsoft Azure, or Google ECM into existing on-premises systems. Where is all the Private Cloud? What do technology providers need to do to make their offerings more compelling? How should enterprise IT executives and buyers define their focus, needs, and roadmap, and communicate that clearly to the providers?
Dec. 7, 2016 07:15 PM EST Reads: 403
SYS-CON Events announced today that Dataloop.IO, an innovator in cloud IT-monitoring whose products help organizations save time and money, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Dataloop.IO is an emerging software company on the cutting edge of major IT-infrastructure trends including cloud computing and microservices. The company, founded in the UK but now based in San Fran...
Dec. 7, 2016 07:00 PM EST Reads: 483
Join Impiger for their featured webinar: ‘Cloud Computing: A Roadmap to Modern Software Delivery’ on November 10, 2016, at 12:00 pm CST. Very few companies have not experienced some impact to their IT delivery due to the evolution of cloud computing. This webinar is not about deciding whether you should entertain moving some or all of your IT to the cloud, but rather, a detailed look under the hood to help IT professionals understand how cloud adoption has evolved and what trends will impact th...
Dec. 7, 2016 06:00 PM EST Reads: 2,667
In his session at 19th Cloud Expo, Claude Remillard, Principal Program Manager in Developer Division at Microsoft, contrasted how his team used config as code and immutable patterns for continuous delivery of microservices and apps to the cloud. He showed how the immutable patterns helps developers do away with most of the complexity of config as code-enabling scenarios such as rollback, zero downtime upgrades with far greater simplicity. He also demoed building immutable pipelines in the cloud ...
Dec. 7, 2016 06:00 PM EST Reads: 1,872
"We are the public cloud providers. We are currently providing 50% of the resources they need for doing e-commerce business in China and we are hosting about 60% of mobile gaming in China," explained Yi Zheng, CPO and VP of Engineering at CDS Global Cloud, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 7, 2016 05:45 PM EST Reads: 1,106
Businesses and business units of all sizes can benefit from cloud computing, but many don't want the cost, performance and security concerns of public cloud nor the complexity of building their own private clouds. Today, some cloud vendors are using artificial intelligence (AI) to simplify cloud deployment and management. In his session at 20th Cloud Expo, Ajay Gulati, Co-founder and CEO of ZeroStack, will discuss how AI can simplify cloud operations. He will cover the following topics: why clou...
Dec. 7, 2016 05:15 PM EST Reads: 931